Owen Garrick - Amarantus Bioscience Co Advisor
AMBS Stock | USD 0.0001 0.00 0.00% |
Insider
Owen Garrick is Co Advisor of Amarantus Bioscience Holdings
Phone | 650-862-5391 |
Web | https://www.amarantus.com |
Similar Executives
Found 8 records | INSIDER Age | ||
George Hill | Ascletis Pharma | 72 | |
Hejingdao Wu | Ascletis Pharma | 49 | |
John MBA | Ascletis Pharma | N/A | |
Yuemei Yan | Ascletis Pharma | 53 | |
Jinzi Wu | Ascletis Pharma | 60 | |
Handan He | Ascletis Pharma | 61 | |
Kristjan Gudmundsson | Ascletis Pharma | 55 | |
Ming CPA | Ascletis Pharma | N/A |
Amarantus Bioscience Leadership Team
Elected by the shareholders, the Amarantus Bioscience's board of directors comprises two types of representatives: Amarantus Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amarantus. The board's role is to monitor Amarantus Bioscience's management team and ensure that shareholders' interests are well served. Amarantus Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amarantus Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
Paula MD, Chief Diagnostics | ||
Elise MS, VP Management | ||
Aimee Boutcher, Director Relations | ||
Robert Harris, Compliance Officer, Independent Director, Chairman of Governance and Nominating Committee, Member of Compensation Committee and Member of Audit Committee | ||
John Commissiong, Chief Scientific Officer, Director and Member of Scientific Advisory Board | ||
Brian Harvey, Chief Advisors | ||
Owen Garrick, Co Advisor | ||
Richard MD, Chief Corp | ||
Gerald Commissiong, CEO and President and Director | ||
Ravi Kiron, Sr Devel |
Amarantus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Amarantus Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Current Valuation | 6.59 M | |||
Shares Outstanding | 68.27 M | |||
Price To Earning | (0.01) X | |||
Price To Book | 53.19 X | |||
EBITDA | (20.79 M) | |||
Net Income | (10.58 M) | |||
Cash And Equivalents | 178 | |||
Total Debt | 20.72 M | |||
Debt To Equity | 0.84 % | |||
Current Ratio | 0.02 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Amarantus Pink Sheet Analysis
When running Amarantus Bioscience's price analysis, check to measure Amarantus Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amarantus Bioscience is operating at the current time. Most of Amarantus Bioscience's value examination focuses on studying past and present price action to predict the probability of Amarantus Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amarantus Bioscience's price. Additionally, you may evaluate how the addition of Amarantus Bioscience to your portfolios can decrease your overall portfolio volatility.